Despite potentially curative surgery, the 5-year survival rate for patients with esophageal cancer (EC) is approximately 25%, and thus, additional therapies have been explored to improve outcomes.
proved recurrence-free survival (RFS) and overall survival (OS) in patients with EC treated with preoperative chemoradiation vs surgery alone.
2,3 Historically, cisplatin-based regimens demonstrate higher tumor response rates but exhibit increased toxic effects compared with carboplatin-based regimens, which have become an attractive alternative.
2-4
While preoperative chemoradiation with cisplatin and fluorouracil (cis/5FU) or carboplatin and paclitaxel (carbo/pac) have been studied individually in EC, comparative randomized trials are lacking. Given the cis/5FU and carbo/pac usage during 2 time periods (2005-2012 and 2011-present, respectively) at our institution, we hypothesized that despite concerns of toxic effects there would be no difference in treatment completion be- .05 were considered statistically significant. Patient informed consent was waived due to the retrospective nature of the study.
Results | Fifty-seven patients underwent esophagectomy for EC and 47 received neoadjuvant therapy. Thirty-eight chemoradiation cases used cis/5FU (n = 24) or carbo/pac (n = 14) and compose the study cohort. No differences existed between cohorts except postsurgical follow-up time, consistent with the programmatic change in chemotherapeutic regimens (Table) . Intended preoperative chemoradiation was completed in 24 patients (100%) treated with cis/5FU (100%) and 9 patients (64.3%) treated with carbo/pac (64.3%) (P = .002). Treatment interruptions in the cis/5FU and carbo/pac cohorts occurred in 8 patients (33.3%) and 6 patients (42.9%), respectively (P = .03 (Figure) .
Discussion | Although neoadjuvant cis/5FU-based chemoradiation has demonstrated survival advantages in EC, patient tolerance can be challenging due to higher rates of grade 3 toxic effects. 4,5 After the CROSS trial 3 confirmed carbo/pac as an acceptable alternative therapy, many institutions shifted to this regimen. Despite concerns of toxic effects, our data demonstrate cis/5FU-treated patients completed preoperative therapy with fewer interruptions. Although not statistically significant, the cis/5FU cohort demonstrated increased RFS and OS vs carbo/pac-treated patients. The higher pathologic complete response rate, a feature prognostic for survival, 6 may explain this finding but interpretation is limited by the small cohort size and short follow-up in the carbo/pac group given its relatively recent institutional use. Granted, patient performance status alters phyiscians' chemotherapy selection and introduces potential selection bias. 5 However, cis/5FU usage was nearly uniform before our carbo/pac transition, creating 2 chemotherapy eras wherein most patients now receive carbo/pac, regardless of performance status.
Conclusions | Preoperative use of cis/5FU in patients with EC should still be considered because it may yield higher pathologic complete response rates, lower postoperative complica- Cis/5FU
Kaplan-Meier product limit method estimation of (A) recurrence-free survival and (B) overall survival stratified by preoperative chemoradiation regimen of carboplatin and paclitaxel (Carbo/Pac) or cisplatin and fluoruracil (Cis/5FU) in patients who underwent potentially curative esophagectomy for esophageal malignancy. 
Variation in Weight and Obesity Comorbidities After Open Roux-en-Y Gastric Bypass by Health Insurance: Medicaid vs Medicare vs Private vs Self-Pay in 4225 Bariatric Outcomes Longitudinal Database Patients
Open Roux-en-Y gastric bypass (ORYGB) is performed primarily on patients with complicated intra-abdominal pathology, massive obesity not conducive to laparoscopy, or prohibitive medical conditions. Gomez et al 1 reported significant variation in weight loss and resolution of medical problems in superobese patients after biliopancreatic diversion/duodenal switch. However, to our knowledge, whether health insurance status similarly influences the results of patients undergoing ORYGB is unknown. Therefore, the objective of this study was to identify variation in ORYGB outcomes by health insurance status.
Methods | Data from 4225 Surgical Review Corporation Bariatric Outcomes Longitudinal Database 2 patients who underwent ORYGB were analyzed retrospectively in 4 groups: Medicaid (n = 272), Medicare (n = 632), private insurance (n = 3253), and self-pay (n = 68). General linear models included baseline and postoperative data and were modified for binomial distribution of dichotomous variables. 3 This investigation was approved by the data access committee of the Surgical Review Corporation and the institutional review board of Our Lady of Lourdes Medical Center, Camden, New Jersey. This was a retrospective study, ruled exempt by both the data access committee of the Surgical Review Corporation and the institutional review board of Our Lady of Lourdes; therefore, no patient consent was required.
Results | The mean (SD) age was 41 (11) years for Medicaid patients, 53 (11) years for Medicare patients, 40 (11) years for privately insured patients, and 40 (12) years for self-pay (P < .001). Medicaid patients were 84% women and 16% men, Medicare patients were 72% women and 28% men, private insurance was 75% women and 25% men, and selfpay was 63% women and 37% men (P < .001). Mean (SD) weight at 6 months was 113 (29) kg for Medicaid patients, 111 (31) kg for Medicare patients, 104 (25) kg for privately insured patients, and 115 (34) kg for self-pay (P < .05). Body mass index (calculated as weight in kilograms divided by height in meters squared) at 6 months was 40 (9) for all Medicaid, Medicare, and self-pay patients and was 37 (8) for privately insured patients. Weight and BMI did not vary among the 4 insurance groups after 6 months. Other results are displayed in Tables 1 and 2 . Through 24 months, abdominal hernia, abdominal panniculitis, cholelithiasis, gastroesophigal reflux disease, dyslipidemia, and tobacco use varied significantly according to health insurance status. Hypertension, back pain, leg edema, musculoskeletal pain, impaired functional status, and asthma varied through 12 months as did depression through 18 months. Body mass index, obstructive sleep apnea, obesity hypoventilation syndrome, stress urinary incontinence, gout, and psychological impairment differed up to 6 months. Alcohol use increased in self-pay at 18 months. No other comorbidities varied.
Discussion | The results of this study indicate that ORYGB outcomes vary by health insurance. Weight and body mass index were lowest among private patients through 6 months but did not vary significantly by insurance thereafter. Hypertension was lowest in self-pay through 12 months, with Medicaid carrying the highest rates of the 4 insurance types and hypertension affecting Medicaid and privately insured patients intermediate to the other groups. Early (6 months) obstructive sleep apnea resolved best for self-pay
